Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.50
+1.4%
$3.96
$3.27
$7.26
$21.70M0.67,277 shs10,494 shs
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$1.35
-6.9%
$2.04
$1.34
$9.69
$76.40M0.91332,562 shs438,450 shs
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
$1.91
+1.1%
$2.35
$1.49
$6.06
$89.14M1.82470,615 shs162,747 shs
Zura Bio Limited stock logo
ZURA
Zura Bio
$1.27
-6.6%
$1.46
$1.07
$6.35
$82.60M0.06377,376 shs218,258 shs
The 10 Best Stocks to Own: Spring 2025 Cover

Discover the 10 best stocks to own in Spring 2025, carefully selected for their growth potential amid market volatility. This exclusive report highlights top companies poised to thrive in uncertain economic conditions—download now to gain an investing edge.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00%-10.03%-12.28%-17.84%-42.43%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
0.00%-19.16%-33.17%-55.88%-83.73%
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
0.00%+1.06%-22.67%+15.76%-40.31%
Zura Bio Limited stock logo
ZURA
Zura Bio
0.00%-8.99%+5.42%-49.40%-45.47%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.7524 of 5 stars
0.03.00.00.01.91.70.6
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
3.6324 of 5 stars
4.54.00.00.02.61.70.6
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
3.9377 of 5 stars
3.55.00.00.03.13.31.3
Zura Bio Limited stock logo
ZURA
Zura Bio
2.1583 of 5 stars
3.50.00.00.02.43.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
3.00
Buy$9.33591.36% Upside
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
3.00
Buy$16.25750.79% Upside
Zura Bio Limited stock logo
ZURA
Zura Bio
3.00
Buy$15.001,085.77% Upside

Current Analyst Ratings Breakdown

Latest NAII, TCRX, VIGL, and ZURA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/26/2025
Zura Bio Limited stock logo
ZURA
Zura Bio
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$20.00 ➝ $19.00
3/26/2025
Zura Bio Limited stock logo
ZURA
Zura Bio
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
3/26/2025
Zura Bio Limited stock logo
ZURA
Zura Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $10.00
3/14/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$10.00
3/14/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$24.00 ➝ $13.00
3/14/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$17.00 ➝ $14.00
3/7/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$14.00 ➝ $3.00
3/6/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
3/5/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$7.00
3/5/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$11.00 ➝ $9.00
1/24/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 3/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$121.85M0.18N/AN/A$12.77 per share0.27
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$2.82M27.13N/AN/A$3.15 per share0.43
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
N/AN/AN/AN/A$3.24 per shareN/A
Zura Bio Limited stock logo
ZURA
Zura Bio
N/AN/AN/AN/A$1.85 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.29N/AN/A-6.26%-9.36%-4.82%5/12/2025 (Estimated)
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$89.22M-$1.15N/AN/AN/A-1,188.88%-58.72%-36.02%5/12/2025 (Estimated)
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
-$82.64M-$2.06N/AN/AN/AN/A-83.89%-65.34%5/6/2025 (Estimated)
Zura Bio Limited stock logo
ZURA
Zura Bio
-$69.24M-$0.53N/AN/AN/AN/A-37.36%-29.81%5/8/2025 (Estimated)

Latest NAII, TCRX, VIGL, and ZURA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/25/2025Q4 2024
Zura Bio Limited stock logo
ZURA
Zura Bio
-$0.17-$0.08+$0.09-$0.08N/A$0.00 million
3/13/2025Q4 2024
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
-$0.49-$0.57-$0.08-$0.57N/AN/A
3/5/2025Q4 2024
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$0.27-$0.29-$0.02-$0.30$1.43 million$0.67 million
2/14/2025Q2 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$34.08 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
N/AN/AN/AN/AN/A
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
N/AN/AN/AN/AN/A
Zura Bio Limited stock logo
ZURA
Zura Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.70
1.50
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
0.13
9.56
9.56
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
N/A
3.72
3.72
Zura Bio Limited stock logo
ZURA
Zura Bio
N/A
10.36
10.36

Institutional Ownership

CompanyInstitutional Ownership
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
82.83%
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
83.64%
Zura Bio Limited stock logo
ZURA
Zura Bio
61.14%

Insider Ownership

CompanyInsider Ownership
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
20.90%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
2.76%
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
33.03%
Zura Bio Limited stock logo
ZURA
Zura Bio
22.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.20 million4.90 millionNot Optionable
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
10056.59 million51.90 millionNot Optionable
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
4046.67 million27.38 millionNot Optionable
Zura Bio Limited stock logo
ZURA
Zura Bio
365.29 million50.86 millionOptionable

Recent News About These Companies

FY2025 EPS Estimates for Zura Bio Cut by Cantor Fitzgerald
Brokers Set Expectations for Zura Bio FY2025 Earnings
Zura Bio Limited stock logo
Analysts Set Expectations for Zura Bio FY2025 Earnings
Q1 Earnings Estimate for Zura Bio Issued By Leerink Partnrs
Zura Bio Limited stock logo
Zura Bio (NASDAQ:ZURA) Releases Quarterly Earnings Results
Zura Bio Limited stock logo
Zura Bio's (ZURA) Buy Rating Reaffirmed at Guggenheim
Guggenheim Reiterates "Buy" Rating for Zura Bio (NASDAQ:ZURA)
Zura Bio (ZURA) Projected to Post Earnings on Thursday

New MarketBeat Followers Over Time

Media Sentiment Over Time

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.50 +0.05 (+1.30%)
As of 03/28/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

TScan Therapeutics stock logo

TScan Therapeutics NASDAQ:TCRX

$1.35 -0.10 (-6.90%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$1.35 0.00 (0.00%)
As of 03/28/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Vigil Neuroscience stock logo

Vigil Neuroscience NASDAQ:VIGL

$1.91 +0.02 (+1.06%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$1.91 0.00 (0.00%)
As of 03/28/2025 05:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

Zura Bio stock logo

Zura Bio NASDAQ:ZURA

$1.26 -0.09 (-6.64%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$1.38 +0.12 (+9.09%)
As of 03/28/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.